This site is intended for health professionals only

Tuesday, 9 February 2010

Login: Register | Forgotten password

Newsletter sign up

E-mail sign-up
-

Advertisement

-

Advertisement

-

Advertisement

-

Advertisement

-

Advertisement

Advertisement

Advertisement

Main Page Content:

Answerback

Does foramen closure improve migraine?

12 Feb 08

Q. Should we be investigating patients with migraine to see if they have a patent foramen ovale? Are there any particular clinical features of the migraine that make this more likely? How common is it and what evidence is there that closing the foramen improves the migraines?


A. During fetal development, the foramen ovale allows blood to flow from the right to left atrium, facilitating circulation of oxygenated blood. Anatomical closure usually occurs during early childhood but remains patent, maintaining a right-to-left shunt, in about one-quarter of the population.

There is persuasive evidence of an epidemiological link between migraine with aura and the presence and size of patent foramen ovale. However, there is no evidence for a link between this and migraine without aura. The prevalence of migraine with aura is very high in patients with patent foramen. Migraine with aura is present in 18 to 43% of people with right to left shunt, significantly higher values than in the general population of about 5%.

Migraine with aura prevalence increases with the size of the shunt, from 4% with small shunts to 25% with medium and 53% with large shunts. The prevalence of a foramen in migraine with aura is also higher than expected. Aura migraine attacks are postulated to occur in people with foramen by the passage of vasoactive substances, platelet emboli or paradoxical emboli through the right-left shunt to the brain, bypassing the lung filter and triggering the migraine aura.

Closure of the foramen by implantation procedure is used in stroke and decompression illness. Data indicates that closure may be highly effective in resolving or improving aura migraine attacks in these patients. Overall, 70 to 91% of patients reported resolution or improvement and very low adverse event rates were reported with experienced cardiologists. However, further data is required before closure can be recommended as a treatment for migraine with aura. The MIST trial was designed to provide grade A evidence for this and full results are expected shortly.

Dr Andy Dowson is director of the King’s Headache Service, King’s College Hospital, London


Post and bookmark this story at the following sites:What is this?

Post your comment

You must fill in all fields marked *

12 Feb 08

You must be logged in to add a comment

 

Main site navigation:
Secondary site navigation:
Main site navigation end
-

Advertisement

-

Advertisement

-

Advertisement

-

Advertisement

-

Advertisement

-

Advertisement

-
 
-
Abacus E-media
Abacus e-Media
St. Andrews Court
St. Michaels Road
Portsmouth
PO1 2JH
-

Advertisement